Cellular and T cell engager Immunotherapy
iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
María-Victoria Mateos, MD, PhD
Professor
University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
Salamanca, Spain